Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema
Purpose. To investigate the choroidal vascularity index (CVI) as a prognostic factor for the visual efficacy of antivascular endothelial growth factor (VEGF) treatment in diabetic macular edema (DME). Methods. We retrospectively reviewed 92 DME eyes receiving anti-VEGF treatment, which were stratifi...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2021/3033219 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547114674028544 |
|---|---|
| author | Ningxin Dou Shanshan Yu Ching-Kit Tsui Boyu Yang Jianqiang Lin Xi Lu Yue Xu Benjuan Wu Jinfeng Zhao Xiaoling Liang |
| author_facet | Ningxin Dou Shanshan Yu Ching-Kit Tsui Boyu Yang Jianqiang Lin Xi Lu Yue Xu Benjuan Wu Jinfeng Zhao Xiaoling Liang |
| author_sort | Ningxin Dou |
| collection | DOAJ |
| description | Purpose. To investigate the choroidal vascularity index (CVI) as a prognostic factor for the visual efficacy of antivascular endothelial growth factor (VEGF) treatment in diabetic macular edema (DME). Methods. We retrospectively reviewed 92 DME eyes receiving anti-VEGF treatment, which were stratified as responders (≥5 letters gained) and nonresponders (<5 letters gained or lost). Baseline systematic features and optical coherence tomography features, including the CVI, adjusted ellipsoid zone (EZ) reflectivity, subretinal fluid (SRF), and disorganization of the retinal inner layers (DRIL), were evaluated between the two groups. Results. The baseline CVI was significantly lower in nonresponders than in responders (0.66±0.05, 0.69±0.05, and 0.72±0.05, p=0.014). After adjusting for other factors, the baseline CVI, DRIL, SRF, and adjusted EZ reflectivity were significantly associated with visual outcomes (CVI: odds ratio OR=0.17, p=0.006; adjusted EZ reflectivity: OR=0.56, p=0.007; DRIL: OR=6.71, p=0.001; and SRF: OR=0.29, p=0.008). Conclusion. DME patients with a higher CVI, higher adjusted EZ reflectivity, the presence of SRF, and the absence of DRIL at baseline were more likely to gain >5 letters in visual acuity after anti-VEGF treatment. CVI may serve as a novel biomarker for visual response to anti-VEGF treatment in DME. |
| format | Article |
| id | doaj-art-d723e9e12e3d4b3abb9b37dff4525c46 |
| institution | Kabale University |
| issn | 2314-6753 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-d723e9e12e3d4b3abb9b37dff4525c462025-02-03T06:46:01ZengWileyJournal of Diabetes Research2314-67532021-01-01202110.1155/2021/3033219Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular EdemaNingxin Dou0Shanshan Yu1Ching-Kit Tsui2Boyu Yang3Jianqiang Lin4Xi Lu5Yue Xu6Benjuan Wu7Jinfeng Zhao8Xiaoling Liang9State Key Laboratory of OphthalmologyState Key Laboratory of OphthalmologyState Key Laboratory of OphthalmologyState Key Laboratory of OphthalmologyState Key Laboratory of OphthalmologyState Key Laboratory of OphthalmologyState Key Laboratory of OphthalmologyState Key Laboratory of OphthalmologyState Key Laboratory of OphthalmologyState Key Laboratory of OphthalmologyPurpose. To investigate the choroidal vascularity index (CVI) as a prognostic factor for the visual efficacy of antivascular endothelial growth factor (VEGF) treatment in diabetic macular edema (DME). Methods. We retrospectively reviewed 92 DME eyes receiving anti-VEGF treatment, which were stratified as responders (≥5 letters gained) and nonresponders (<5 letters gained or lost). Baseline systematic features and optical coherence tomography features, including the CVI, adjusted ellipsoid zone (EZ) reflectivity, subretinal fluid (SRF), and disorganization of the retinal inner layers (DRIL), were evaluated between the two groups. Results. The baseline CVI was significantly lower in nonresponders than in responders (0.66±0.05, 0.69±0.05, and 0.72±0.05, p=0.014). After adjusting for other factors, the baseline CVI, DRIL, SRF, and adjusted EZ reflectivity were significantly associated with visual outcomes (CVI: odds ratio OR=0.17, p=0.006; adjusted EZ reflectivity: OR=0.56, p=0.007; DRIL: OR=6.71, p=0.001; and SRF: OR=0.29, p=0.008). Conclusion. DME patients with a higher CVI, higher adjusted EZ reflectivity, the presence of SRF, and the absence of DRIL at baseline were more likely to gain >5 letters in visual acuity after anti-VEGF treatment. CVI may serve as a novel biomarker for visual response to anti-VEGF treatment in DME.http://dx.doi.org/10.1155/2021/3033219 |
| spellingShingle | Ningxin Dou Shanshan Yu Ching-Kit Tsui Boyu Yang Jianqiang Lin Xi Lu Yue Xu Benjuan Wu Jinfeng Zhao Xiaoling Liang Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema Journal of Diabetes Research |
| title | Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema |
| title_full | Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema |
| title_fullStr | Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema |
| title_full_unstemmed | Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema |
| title_short | Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema |
| title_sort | choroidal vascularity index as a biomarker for visual response to antivascular endothelial growth factor treatment in diabetic macular edema |
| url | http://dx.doi.org/10.1155/2021/3033219 |
| work_keys_str_mv | AT ningxindou choroidalvascularityindexasabiomarkerforvisualresponsetoantivascularendothelialgrowthfactortreatmentindiabeticmacularedema AT shanshanyu choroidalvascularityindexasabiomarkerforvisualresponsetoantivascularendothelialgrowthfactortreatmentindiabeticmacularedema AT chingkittsui choroidalvascularityindexasabiomarkerforvisualresponsetoantivascularendothelialgrowthfactortreatmentindiabeticmacularedema AT boyuyang choroidalvascularityindexasabiomarkerforvisualresponsetoantivascularendothelialgrowthfactortreatmentindiabeticmacularedema AT jianqianglin choroidalvascularityindexasabiomarkerforvisualresponsetoantivascularendothelialgrowthfactortreatmentindiabeticmacularedema AT xilu choroidalvascularityindexasabiomarkerforvisualresponsetoantivascularendothelialgrowthfactortreatmentindiabeticmacularedema AT yuexu choroidalvascularityindexasabiomarkerforvisualresponsetoantivascularendothelialgrowthfactortreatmentindiabeticmacularedema AT benjuanwu choroidalvascularityindexasabiomarkerforvisualresponsetoantivascularendothelialgrowthfactortreatmentindiabeticmacularedema AT jinfengzhao choroidalvascularityindexasabiomarkerforvisualresponsetoantivascularendothelialgrowthfactortreatmentindiabeticmacularedema AT xiaolingliang choroidalvascularityindexasabiomarkerforvisualresponsetoantivascularendothelialgrowthfactortreatmentindiabeticmacularedema |